The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EK | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors | |
| 5 | L01EK04 |
| Active Ingredient | Description | |
|---|---|---|
| Fruquintinib |
Fruquintinib is a selective tyrosine kinase inhibitor of VEGFR-1, -2, and -3 with antitumor effects resulting from suppression of tumour angiogenesis. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| FRUZAQLA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| FRUZAQLA Hard capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
